fcγr  (Bio-Rad)

Journal: medRxiv

Article Title: Early Fc-effector antibody signatures impact COVID-19 disease trajectory

doi: 10.64898/2026.02.18.26346542

Figure Lengend Snippet: A) Heatmap of FcγR-binding antibody responses to SARS-CoV-2 S antigens in mild and severe COVID-19 patients. Binding activity of antibodies to FcγRs was measured for SARS-CoV-2 full-length S, S1 and S2 antigens at days 0, 3, 7, and 46 post-recruitment. Box-and-whisker diagrams showing (B) FcγR2AH and FcγR2AR-binding antibody responses (C) FcγR3AV and FcγR3AF-binding titers, (D) functional monocyte antibody-dependent cellular phagocytosis (ADCP) responses and (E) functional antibody-dependent neutrophil phagocytosis (ADNP) responses against SARS-CoV-2 full-length S, S1 and S2 antigens in mild and severe COVID-19 patients. Box indicates interquartile range (IQR, Q1-Q3), with horizontal line showing the median and vertical lines indicating minimum and maximum. Mann-Whitney U test was performed to compare differences between mild vs. severe patients at each time point. Statistical significance was considered when p ≤ 0.05. F) PCA of antibody responses according to day of recruitment (day 0: blue; day 3: red; day 7: green and day 46: purple). Empty circles represent mild cases, and filled circles represent severe cases. Ellipses show 95% confidence regions. G) Spider plot of the antibody landscape (IgG antibody titers, FcγR-binding activity and FcγR-effector functions) in mild and severe COVID-19 patients. Median percentile for each antibody feature is shown at each timepoint and for each SARS-CoV-2 S antigen.

Article Snippet: For the analysis of FcγR binding PE-Streptavidin (Agilent Technologies, CA, USA) was coupled to recombinant and biotinylated human FcγR2AH/R, FcγR2B, FcγR3AF/R and FcγR3B (Duke Human Vaccine Institute Protein Production Facility).

Techniques: Binding Assay, Activity Assay, Whisker Assay, Functional Assay, MANN-WHITNEY

Journal: Frontiers in Immunology

Article Title: Adenovectored RSV prefusion glycoprotein + soluble glycoprotein combination immunization establishes persistent opsonophagocytic antibody response through IgG3

doi: 10.3389/fimmu.2025.1609779

Figure Lengend Snippet: The AD26.preF/SpreF protein induces an acute FcγR-binding repertoire against both RSV/A F and RSV/B F. (A) Univariate comparisons of baseline (black), placebo-treated (gray), or AD26.preF/SpreF protein-vaccinated (gold) participants at the indicated timepoints for FcγRIIA, FcγRIIB, FcγRIIIA, and FcγRIIIB against RSV F subtype A. (B) Same as (A) but for RSV-F subtype B. Statistical comparisons were done using an initial Wilcox test followed by a Bonferroni correction for multiple comparisons. Comparisons were made for recipients of AD26.preF/SpreF protein against placebo at the same timepoint. Bonferroni-corrected p -values ( q -values) were represented above the timepoints with * q < 0.05, ** q < 0.01, and *** q < 0.001; comparisons whose q -value was ≥ 0.05 were left unlabeled. Data was plotted as a box and whisker showing median, interquartile ranges, and ranges. Individual data points were superimposed on each box and whisker plot. Values were plotted as binding mean fluorescence units (MFI) quantified as arbitrary units (A.U.) via multiplexed flow cytometry.

Article Snippet: For FcγR binding, a biotinylated PE-streptavidin coupled recombinant human FcγR protein (Agilent Technologies, Santa Clara, CA, USA) was used as the secondary probe.

Techniques: Binding Assay, Whisker Assay, Fluorescence, Flow Cytometry